We are pulmonary hypertension (PH) professionals united in our vision for a world without pulmonary vascular disease (PVD). We believe we can achieve this together, and we won’t stop until we do.
PVRI 2026 Awards — Nominations now open
Help us celebrate excellence in PH research and care. PVRI members can now nominate colleagues for our 2026 Awards, to be presented at the Gala Dinner in Dublin. Deadline is 1 December 2025.
Our PVRI Digital Webinar Series alternates between 'Cutting Edge Innovation in Clinical & Experimental PH' and 'Living Legends in PH: History & Personal Perspectives' sessions. Don't miss out!
This November, we’re coming together as one global team to shine a light on PH research and innovation during PH Awareness month through our new fundraising challenge: Breath Beyond Borders. PVRI friends across the world are taking on a personal challenge that pushes their limits. Find out how you can get involved.
Join us 28 January – 1 February as we celebrate 20 years of progress and innovation in PH. This year’s programme highlights advances in PAH, CTEPH, and PH in lung disease, with sessions on emerging therapies, precision medicine, and future directions.
'Microbes/Parasites and Sex Differences in PVDs' is part of the Virtual Symposium Series by the iPVD, a global education programme that highlights top-notch research on inflammation and infectious PVD.
The 'Living Legends in PH: History and Personal Perspectives' talks will feature remarkable people who have made major contributions to the field of pulmonary hypertension, bringing their science and personal stories to the worldwide PH community. Each talk will include a junior and senior facilitator to introduce the speaker and lead the discussion.
Una sesión concisa y dirigida por expertos sobre la hipertensión pulmonar del Grupo 2—diagnóstico, clasificación actualizada y estrategias de tratamiento—con un análisis de caso en vivo.
A concise, expert-led session in Spanish exploring Group 2 pulmonary hypertension—its diagnosis, updated classification, and treatment strategies—featuring a live case discussion.
This webinar brings together leading experts to explore the urgent need for new therapies in bronchopulmonary dysplasia-associated pulmonary hypertension. You’ll gain a clear overview of current care, key research gaps, and the real-world challenges of designing meaningful trials for preterm infants — all aimed at advancing treatment for this under-recognised condition.
Pulmonary arterial hypertension (PAH) is a chronic, progressive, and ultimately life-threatening disease characterized by vascular remodeling and increasing pulmonary vascular resistance. Despite significant advances in diagnostic tools and therapeutic strategies, clinical intervention often begins only when patients become symptomatic—typically at New York Heart Association (NYHA) functional class II or higher.
Children with single ventricle heart disease (SVHD) demonstrate decreased arginine/NO metabolism following Stage 2 (Glenn) palliation, associated with poor postoperative outcomes. It is unknown if arginine dysregulation persists at Stage 3 (Fontan).
These annual awards are given in recognition of outstanding contributions to the field of pulmonary hypertension. They celebrate notable achievements made by special individuals across the world. The PVRI Lifetime Achievement Award 2025, the PVRI Achievement Awards 2025 and the PVRI Special Recognition Award will be presented at PVRI 2026 Dublin.
We’re excited to announce the relaunch of the PVRI Digital Webinar Series, beginning September 2025. This free monthly series, open to all, brings together the global PH community for keynote presentations, rich discussion, and the opportunity to learn cutting-edge new research.
This PH Awareness Month, we’re inviting you to join the global PVRI community for our very first Breath Beyond Borders challenge. Throughout November, PVRI members and friends around the world will be taking on personal challenges — walking, running, cycling, speed skating, or even playing the piano — to shine a light on PH research and innovation, and raise funds for PVRI along the way.
Our Pulmonary Hypertension Global Patient Survey (PHGPS), the largest survey to date to explore the perspectives of patients with PH at a global scale, has released initial findings from its adult cohort of 3,329 patients living with PH.
